Drug Trial Radar · NCT07681674
Bicycle Continued Access Protocol (BiCAP) for Participants Receiving a Bicycle Investigational Product
Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Aug 1, 2026
Primary completion
May 30, 2030
Study completion May 30, 2030
Sponsor
- Lead sponsor
- BicycleTx LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jul 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
BiCAP-201 trial offers continued access to Bicycle investigational product treatments zelenectide pevedotin, nuzefatide pevedotin, and BT7480 for participants currently receiving and deriving clinical benefit from one of these treatments in a Bicycle Therapeutics-sponsored clinical trial. Bicycle Therapeutics will continue to monitor longer term safety of these treatments.
Conditions
- Advanced Solid Tumors
Interventions
Zelenectide pevedotinDrug
Participants will continue on the same treatment regimen they were receiving in their parent study.
BT7480Drug
Participants will continue on the same treatment regimen they were receiving in their parent study.
Nuzefatide pevedotinDrug
Participants will continue on the same treatment regimen they were receiving in their parent study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Monitor safety for participants receiving a Bicycle investigational productTime frame: Up to 48 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.